Selective blockade of cholecystokinin type B receptors with L-365,260 does not impair gallbladder contraction in normal humans

American Journal of Gastroenterology

Volumn 91, Issue 3, 1996, Pages 569-573

  Grasing, K ^a   Freedholm, D ^b   Murphy, M G ^b   Swigar, M ^b   Russer, T ^b   Nosher, J ^b   Lin, J ^b   Frame, V ^b   Clarke, L ^b   Seibold, J R ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; PENTAGASTRIN; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ECHOGRAPHY; GALLBLADDER CONTRACTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANALYSIS OF VARIANCE; BENZODIAZEPINONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GALLBLADDER; GALLBLADDER EMPTYING; HUMANS; MALE; MIDDLE AGED; PHENYLUREA COMPOUNDS; RECEPTORS, CHOLECYSTOKININ; REFERENCE VALUES; TIME FACTORS;

EID: 0029961585     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Ivy AC, Olberg E. A hormone mechanism for gall bladder contraction and evacuation. Am J Physiol 1928;86:599-613.
2. Go VLW. The physiology of cholecystokinin. In: Bloom SR, ed. Gut hormones. Edinburgh: Churchill Livingstone, 1978: 203-7.
3. Lotti VJ, Pendleton RG, Gould RJ, et al. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist. J Pharmacol Exp Ther 1987;241:103-9.
4. Woodruff GN, Hill DR, Boden P, et al. Functional role of CCK receptors. Neuropeptides 1991;19:45-56.
5. Raiteri M, Paudice P, Vallebuona F. Release of cholecystokinin in the central nervous system. Neurochem Int 1993;22:519-27.
6. Moran TH, McHugh PR. Cholecystokinin receptors. In: Bjorkludn A, Hokfelt T, Kuhar MJ, eds. Handbook of chemical neuroanatomy. New York: Elsevier Science Publishers, 1990: 455-75.
7. Bock MG, Dipardo RM, Evans BE, et al. Bezodiazepine gastrin and cholecystokinin receptor ligands: L-365,260. J Med Chem 1989;32: 13-8.
8. Lotti VJ, Chang RS. A new potent and selective non-peptide gastrin antagonist brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol 1989;162:273-80.
9. Murphy MG, Sytnik B, Kovac TOG, et al. The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans. Clin Pharmacol Ther 1993;54:553-9.
10. Harro J, Vasar E, Bradwejn J. CCK in animal and human research on anxiety. Trends Pharm Sci 1993;14:245-9.
11. Schiantarelli P. Therapeutic potential of cholecystokinin receptor antagonists in CNS disorders. Pharmacol Res 1993;28:1-9.
12. Singh L, Lewis AS, Field MJ, et al. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci USA 1991;88:1130-3.
13. Bradwejn J, Koszychi D, Dutertra A. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 1994;51:486-93.
14. Everson GT, Braverman DZ, Johnson ML, et al. A critical evaluation of real-time ultrasonagraphy for the study of gallbladder volume and contraction. Gastroenterology 1980;83:773-6.
15. Dodds WJ, Groh WJ, Darweesh RMA, et al. Sonographic measurement of gallbladder volume. Am J Radiol 1985;146:1009-11.
16. Chen IW, Lin JH, Dorley J. Quantitation of a new cholecystokinin and gastrin receptor antagonist (L-365,260) in dog and rat plasma by high-performance liquid chromatography. J Chromatograph 1992;576:363-7.
17. Bradwejn J. Neurobiological investigations into the role of cholecystokinin in panic disorder. J Psychiatr Neurosci 1993;18:178-88.
18. Liddle RA, Gertz BJ, Kanayama S, et al. Effects of a novel cholecytokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. J Clin Invest 1989;84:1220-5.
19. Niederau C, Heintges T, Rovati L, et al. Effects of loxiglumide on gallbladder emptying in healthy volunteers. Gastroenterology 1989; 97:1331-6.
20. van Liesum PA, Hopman WPM, Pieters GFFM, et al. Postprandial gallbladder motility during long-term treatment with the long-acting somatostatin analog SMS 201-995 in acromegally. J Clin Endocrin Metab 1989;69:557-62.
21. Grasing K, Szeto H. Diurnal variation in continuous measures of the rat EEG power spectra. Physiol Behav 1992;51:249-54.